MedTrace Logo

Intense Airway Eosinophilia in Asthma

NCT03696914 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 918

Last updated 2018-10-05

No results posted yet for this study

Summary

In asthma, the type and importance of the inflammatory response in the airways has allows identification of different phenotypes. Of these, one of the most common is eosinophilic asthma, based on induced sputum differential cell count. Patients with severe asthma and an eosinophilic asthma phenotype have different pathophysiological characteristics than those seen in patients with with mild asthma. However, few studies have compared patients with eosinophilic phenotype according to the severity of asthma. In addition, the stability of the phenotype based on the sputum results has been criticized.

This study aims to describe the characteristics of patients with eosinophilic asthma phenotype according to the severity of asthma and determine the stability of the phenotype.

Conditions

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Laval University

    lead OTHER

Principal Investigators

  • Louis-Philippe Boulet, MD · IUCPQ-UL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-06
Primary Completion
2018-04-18
Completion
2018-08-03

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03696914 on ClinicalTrials.gov